Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19
Vural, Ipek Eren
JournalJournal of Law and the Biosciences
PublisherOxford University Press
MetadataShow full item record
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14655
- From sandbox to pandemic: Agile reform of Canadian drug regulation.
- Authors: Eren Vural I, Herder M, Graham JE
- Issue date: 2021 May 15
- A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation.
- Authors: Lexchin J, Mintzes B
- Issue date: 2014
- Trust and transparency in times of crisis: Results from an online survey during the first wave (April 2020) of the COVID-19 epidemic in the UK.
- Authors: Enria L, Waterlow N, Rogers NT, Brindle H, Lal S, Eggo RM, Lees S, Roberts CH
- Issue date: 2021
- Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19.
- Authors: Lexchin J, Graham J, Herder M, Jefferson T, Lemmens T
- Issue date: 2021 Jan
- When predictions are used to allocate scarce health care resources: three considerations for models in the era of Covid-19.
- Authors: Kent DM, Paulus JK, Sharp RR, Hajizadeh N
- Issue date: 2020